HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
This study is designed to evaluate the antitumor activity of patritumab deruxtecan in
participants with metastatic or locally advanced NSCLC with an activating EGFR mutation (exon
19 deletion or L858R) who have received and progressed on or after at least 1 EGFR TKI...
Age: 18 years - 66+
Gender: All
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus
atezolizumab compared with placebo in participants with unresectable locally advanced
esophageal squamous cell carcinoma and who have completed definitive concurrent
chemoradiation t...
Age: 18 years - 66+
Gender: All
FAST (Focused Abbreviated Screening Technique)-MRI Study
The purpose of this study is to compare the diagnostic value of a reconstructed abbreviated
Magnetic Resonance Imaging (MRI) from a full clinical exam, compared to ultrasound (US) for
screening of liver cancer. Blood markers will be evaluated to determine their correl...
Age: 18 years - 66+
Gender: All
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate the efficacy and safety of atezolizumab in
combination with tiragolumab compared with durvalumab in participants with locally advanced,
unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two
c...
Age: 18 years - 66+
Gender: All
First-in-human Study of DRP-104 as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors.
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of DRP-104 administered via intravenous infusion as a single agent and in combination with atezolizumab in patients with advanced...
Age: 18 years - 66+
Gender: All
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of small cell lung cancer that has...
Age: 18 years - 66+
Gender: All
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer
This is a Phase 2, global, multicenter, open label, single arm study designed to evaluate the efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of AK104 monotherapy in adult subjects with previously treated recurrent or metastatic cervical carcino...
Age: 18 years - 66+
Gender: Female
A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment
This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of atezolizumab given in combination with cabozantinib versus cabozantinib alone in participants with inoperable, locally advanced, or metastatic renal cell carci...
Age: 18 years - 66+
Gender: All
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
This study is designed to evaluate the efficacy and safety of mirvetuximab soravtansine (MIRV) in patients with platinum-resistant high-grade serous epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of Folate Rece...
Age: 18 years - 66+
Gender: Female
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will concurrently enroll patients with four distinct advanced malignancies in 5 separate tumor cohorts. The four can...
Age: 18 years - 66+
Gender: All
Hypofractionated Radiotherapy in Elderly Patients With Head & Neck Squamous Cell Carcinoma
The purpose of this research study is to investigate a shorter radiation treatment schedule
for head and neck cancers in patients 70 years of age and older.
Standard radiation treatment for head and neck patients normally requires that the patient
travel to the ...
Age: 70 years - 66+
Gender: All
A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
This study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and
etoposide (CE) compared with placebo plus atezolizumab and CE in participants with
chemotherapy-naive extensive-stage small cell lung cancer (ES-SCLC). Eligible participants
...
Age: 18 years - 66+
Gender: All
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer
This trial studies how well atezolizumab added to the usual radiation therapy works in
treating patients with stage I-IIA non-small cell lung cancer. Immunotherapy with monoclonal
antibodies, such as atezolizumab, may help the body's immune system attack the cancer,...
Age: 18 years - 66+
Gender: All
A Study of TheraT® Vector(s) Expressing HPV 16+ in Patients With HPV 16+ Confirmed Cancers
This is an First in Human (FIH) Phase I/II, multinational, multicenter, open-label study of
HB-201 single vector therapy and HB-201 & HB-202 two-vector therapy in patients with HPV 16+
confirmed cancers comprising two parts: Phase I Dose Escalation and Phase II Dose...
Age: 18 years - 66+
Gender: All
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation) therapy works in comparison to standard-dose chemoradiation in treating patients with early-stage anal cancer. Drugs used in chemotherapy, such as mitomycin, fluorouracil, and c...
Age: 18 years - 66+
Gender: All
TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
The purpose of this study is to compare the efficacy of TAK-788 as first-line treatment with
that of platinum-based chemotherapy in participants with locally advanced or metastatic
non-small cell lung cancer (NSCLC) whose tumors harbor epidermal growth factor receptor...
Age: 18 years - 66+
Gender: All
Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)
The purpose of this research study is to study the effect of giving nivolumab with
CCR2/5-inhibitor or anti-IL-8 before surgery, and after surgery, with the goal of determining
if this medicine results in:
1. A significant immune response against their tumor (which t...
Age: 18 - 99 years
Gender: All
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase III trial studies how well letrozole with or without paclitaxel and carboplatin
works in treating patients with stage II-IV low-grade serous carcinoma of the ovary,
fallopian tube, or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of
...
Age: 18 years - 66+
Gender: Female
Tisch Cancer Institute-BMS Study # CA027-005: Neoadjuvant Nivolumab + BMS-813160 (CCR2/5-inhibitor) or BMS-986253 (anti-IL-8) for NSCLC or HCC
The purpose of this research study is to study the effect of giving a new cancer medicine before surgery, and after surgery, with the goal of determining if this medicine results in 1) a significant immune response against their tumor (which we will see in the tumor tha...
Age: 18 - 99 years
Gender: All
Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients
Combination immune checkpoint inhibitor and DNA vaccine will result in clearance of HPV DNA
biomarkers (oral and/or plasma) for patients with persistent HPV-16 E6/E7 DNA (HPV biomarker)
after treatment with curative intent.
Age: 18 years - 66+
Gender: All